Recent Company News

• 06:34 AM ET Jul 03, 2025
  

  Financials, real estate and retail the best performers; tech and healthcare main laggards:

• 06:10 AM ET Jul 03, 2025
  

  StreetAccount Macro Headlines:

• 02:51 AM ET Jul 03, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:18 AM ET Jul 03, 2025
  

  Novartis announces top-line results from Phase III GCAptAIN study evaluating Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis (CHF 98.43, 0.00)

• 10:21 AM ET Jul 02, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (81 total)

• 10:30 AM ET Jul 01, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (100 total)

• 08:53 AM ET Jun 27, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:10 AM ET Jun 27, 2025
  

  FDA confirms REMS has been eliminated for approved BCMA- and CD19-directed CAR-T immunotherapies

• 01:32 PM ET Jun 26, 2025
  

  Profound Therapeutics announces multi-year collaboration with Novartis to develop therapeutics for cardiovascular disease (pre-open) (CHF 96.02, 0.00)

• 08:24 AM ET Jun 26, 2025
  

  Idorsia incoming CEO says does not want company to be acquired; wants to remain independent; mentions financial flexibility options -- AWP, citing interview (CHF 2.03, +0.06)